Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2004;94:1451-1457
Published online before print April 29, 2004, doi: 10.1161/01.RES.0000130654.56599.40
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
94/11/1451    most recent
01.RES.0000130654.56599.40v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lochard, N.
Right arrow Articles by Reudelhuber, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lochard, N.
Right arrow Articles by Reudelhuber, T. L.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
(Circulation Research. 2004;94:1451.)
© 2004 American Heart Association, Inc.


Integrative Physiology

Chronic Production of Angiotensin IV in the Brain Leads to Hypertension That Is Reversible With an Angiotensin II AT1 Receptor Antagonist

Nadheige Lochard, Gaétan Thibault, David W. Silversides, Rhian M. Touyz, Timothy L. Reudelhuber

From Laboratories of Molecular Biochemistry of Hypertension (N.L., T.L.R.), Cell Biology of Hypertension (G.T.), and Experimental Hypertension (R.M.T.), Clinical Research Institute of Montreal, Quebec, Canada; and Centre de Recherche en Reproduction Animale (D.W.S.), Faculté de Médecine Vétérinaire de l’université de Montréal, Sainte-Hyacinthe, Quebec, Canada.

Correspondence to Timothy L. Reudelhuber, IRCM, 110, Pine Ave West, Montreal, QC H2W 1R7 Canada. E-mail reudelt{at}ircm.qc.ca

Angiotensin IV (Ang IV) is a metabolite of the potent vasoconstrictor angiotensin II (Ang II). Because specific binding sites for this peptide have been reported in numerous tissues including the brain, it has been suggested that a specific Ang IV receptor (AT4) might exist. Bolus injection of Ang IV in brain ventricles has been implicated in learning, memory, and localized vasodilatation. However, the functions of Ang IV in a physiological context are still unknown. In this study, we generated a transgenic (TG) mouse model that chronically releases Ang IV peptide specifically in the brain. TG mice were found to be hypertensive by the tail-cuff method as compared with control littermates. Treatment with the angiotensin-converting enzyme inhibitor captopril had no effect on blood pressure, but surprisingly treatment with the Ang II AT1 receptor antagonist candesartan normalized the blood pressure despite the fact that the levels of Ang IV in the brains of TG mice were only 4-fold elevated over the normal endogenous level of Ang peptides. Calcium mobilization assays performed on cultured CHO cells chronically transfected with the AT1 receptor confirm that low-dose Ang IV can mobilize calcium via the AT1 receptor only in the presence of Ang II, consistent with an allosteric mechanism. These results suggest that chronic elevation of Ang IV in the brain can induce hypertension that can be treated with angiotensin II AT1 receptor antagonists.


Key Words: angiotensin IV • transgenic model • hypertension • brain renin–angiotensin system




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Kotlo, S. Shukla, U. Tawar, R. A. Skidgel, and R. S. Danziger
Aminopeptidase N reduces basolateral Na+-K+-ATPase in proximal tubule cells
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1047 - F1053.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H.-L. Li, Z.-G. She, T.-B. Li, A.-B. Wang, Q. Yang, Y.-S. Wei, Y.-G. Wang, and D.-P. Liu
Overexpression of Myofibrillogenesis Regulator-1 Aggravates Cardiac Hypertrophy Induced by Angiotensin II in Mice
Hypertension, June 1, 2007; 49(6): 1399 - 1408.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H.-L. Li, M.-L. Zhuo, D. Wang, A.-B. Wang, H. Cai, L.-H. Sun, Q. Yang, Y. Huang, Y.-S. Wei, P. P. Liu, et al.
Targeted Cardiac Overexpression of A20 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction
Circulation, April 10, 2007; 115(14): 1885 - 1894.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. Jankowski, R. Vanholder, M. van der Giet, M. Tolle, S. Karadogan, J. Gobom, J. Furkert, A. Oksche, E. Krause, T. N. Anh Tran, et al.
Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 297 - 302.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
X. C. Li, D. J. Campbell, M. Ohishi, S. Yuan, and J. L. Zhuo
AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats
Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1024 - F1033.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
I. Haulica, W. Bild, and D. N Serban
Review: Angiotensin Peptides and their Pleiotropic Actions
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 121 - 131.
[Abstract] [PDF]